[Pubmed] Fulminant myocarditis and sudden death associated with thymoma-related autoimmunity

Intégration des publications parues sur PUBMED
Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 6501
Enregistré le : 31 mai 2020 09:57
6
Zodiaque :
Âge : 22
Contact :
    Linux Chrome

[Pubmed] Fulminant myocarditis and sudden death associated with thymoma-related autoimmunity

Message par RSS-Bot »


Intractable Rare Dis Res. 2026 Aug 31;15(3):273-276. doi: 10.5582/irdr.2026.01022.

ABSTRACT

Fulminant myocarditis (FM) is a severe, rapidly progressive and life-threatening condition of myocarditis associated with infectious or autoimmune etiologies. Here, we present three patients with an invasive thymoma who had FM, which eventually led to sudden death. The most frequent clinical presentations at onset include palpitations, orthopnea, and acute worsening of myasthenia gravis (MG). Highly elevated myocardial biomarkers and positive autoantibodies against cardiac muscle, skeletal muscle, and neuromuscular junctions were detected in serum. The electrocardiograph (ECG) findings progressed to life-threatening ventricular arrhythmias. Although high-dose methylprednisolone or intravenous immunoglobulin was administered along with advanced respiratory support, profound hemodynamic collapse rapidly occurred, and these patients eventually died within days. This case series underscores the importance of rapid recognition of FM associated with thymoma and early aggressive supportive and immunomodulatory interventions, including consideration of mechanical circulatory support when clinically indicated.

PMID:42643723 | PMC:PMC13504678 | DOI:10.5582/irdr.2026.01022


Source: https://pubmed.ncbi.nlm.nih.gov/4264372 ... 6&v=2.20.1
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur [email protected]


Bonne lecture...
Répondre

Retourner vers « Echos de la recherche »